Desmoid with biweekly methotrexate and vinblastine shows similar effects to weekly administration: A phase II clinical trial.
Adolescent
Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Child
Child, Preschool
Drug Administration Schedule
Female
Fibromatosis, Aggressive
/ diagnosis
Follow-Up Studies
Humans
Kaplan-Meier Estimate
Male
Methotrexate
/ administration & dosage
Middle Aged
Neoplasm Staging
Prognosis
Proportional Hazards Models
Treatment Outcome
Vinblastine
/ administration & dosage
Young Adult
biweekly
clinical benefit rate
desmoid
methotrexate
vinblastine
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
28
05
2020
revised:
27
07
2020
accepted:
11
08
2020
pubmed:
21
8
2020
medline:
22
12
2020
entrez:
21
8
2020
Statut:
ppublish
Résumé
Low-dose methotrexate (MTX) plus vinblastine (VBL) chemotherapy is an effective treatment for desmoid-type fibromatosis (DF). However, previous reports have described a weekly regimen, with no reports available on a biweekly one. The aim of this study was to determine the clinical outcomes of a biweekly regimen in a cohort prospectively treated in our single institution. Since 2010, we have prospectively treated refractory DF patients with biweekly MTX (30 mg/m
Identifiants
pubmed: 32816351
doi: 10.1111/cas.14626
pmc: PMC7648024
doi:
Substances chimiques
Vinblastine
5V9KLZ54CY
Methotrexate
YL5FZ2Y5U1
Types de publication
Clinical Trial, Phase II
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
4187-4194Subventions
Organisme : the Ministry of Education, Culture, Sports, Science and Technology of Japan
ID : 17H01585
Organisme : the National Cancer Center Research and Development Fund
ID : 29-A-3
Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Sarcoma. 2003;7(3-4):153-7
pubmed: 18521380
Jpn J Clin Oncol. 2016 Sep;46(9):845-9
pubmed: 27365524
Cancer Sci. 2020 Nov;111(11):4187-4194
pubmed: 32816351
J Clin Oncol. 2007 Feb 10;25(5):501-6
pubmed: 17290057
Cancer Med. 2019 Sep;8(11):5047-5057
pubmed: 31301110
J Clin Oncol. 1998 Sep;16(9):3021-7
pubmed: 9738571
Am J Clin Pathol. 1982 Jun;77(6):665-73
pubmed: 7091046
Am J Pathol. 2008 Nov;173(5):1518-27
pubmed: 18832571
Oncologist. 2011;16(5):682-93
pubmed: 21478276
Cancer J. 2017 Mar/Apr;23(2):86-91
pubmed: 28410293
Chin J Cancer Res. 2017 Oct;29(5):455-462
pubmed: 29142465
Int J Clin Oncol. 2015 Dec;20(6):1211-7
pubmed: 25899770
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
J Clin Oncol. 1999 Mar;17(3):1086
pubmed: 10071306
J Am Coll Surg. 2013 Sep;217(3):472-80
pubmed: 23816381
Lancet Child Adolesc Health. 2017 Dec;1(4):284-292
pubmed: 30169184
Cancers (Basel). 2012 Feb 07;4(1):88-99
pubmed: 24213228
Cancer. 1989 Sep 15;64(6):1192-4
pubmed: 2766217
Ann Surg Oncol. 2015 May;22(5):1464-70
pubmed: 25341748
Cancer. 2001 Sep 1;92(5):1259-64
pubmed: 11571741
Ann Oncol. 2014 Mar;25(3):578-583
pubmed: 24325833
Ann Surg Oncol. 2018 Jun;25(6):1544-1554
pubmed: 29644533
Pediatr Blood Cancer. 2018 May;65(5):e26943
pubmed: 29316163
Eur J Cancer. 2020 Mar;127:96-107
pubmed: 32004793
PLoS One. 2014 May 01;9(5):e96391
pubmed: 24788118
Ann Surg Oncol. 2009 Sep;16(9):2587-93
pubmed: 19568815
ESMO Open. 2020 Jan;5(1):
pubmed: 31958289
Eur J Cancer. 2017 Sep;83:125-131
pubmed: 28735069
Oncol Lett. 2016 Aug;12(2):1564-1568
pubmed: 27446472
Cancer. 2013 Oct 15;119(20):3696-702
pubmed: 23913621
J Clin Oncol. 2010 Feb 20;28(6):e107-9
pubmed: 20026797
Lancet Oncol. 2019 Sep;20(9):1263-1272
pubmed: 31331699
Ann Surg Oncol. 2016 Jun;23(6):1924-7
pubmed: 26861905